Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Enlarged Prostate Clear all
Active, not recruiting No phase listed Observational

Laser Prostatectomy Database and Registry

NCT00159406
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Registry and Database
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 12:13 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Emsella for Reducing tSUI After HOLEP

NCT07580404
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms, Enlarged Prostate (BPH)
Interventions
Emsella chair
Device
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 12:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

NCT07632742
View directory record Official record
Conditions
Enlarged Prostate (BPH), Benign Prostatic Hyperplasia
Interventions
Magneto 150 holmium laser, Moses 2.0 holmium laser
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 12:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate

NCT07187180
View directory record Official record
Conditions
BPH With Symptomatic Lower Urinary Tract Symptoms, BPH With Urinary Obstruction
Interventions
holmium laser, pulsed thulium laser
Device
Lead sponsor
Smita De
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 12:13 PM EDT
Terminated Not applicable Interventional Results available

Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

NCT01789840
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres, TURP
Device · Procedure
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
50 Years to 79 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jul 22, 2026, 12:13 PM EDT
Completed No phase listed Observational

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

NCT05470751
View directory record Official record
Conditions
Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms, Parkinson Disease, Lower Urinary Tract Symptoms, Detrusor Underactivity, Spinal Cord Injuries
Interventions
Intermittent self-catheterisation
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
West Orange, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Not applicable Interventional Results available

3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization

NCT03164629
View directory record Official record
Conditions
Enlarged Prostate
Interventions
cone-beam CT 3D Emboguide
Device
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 79 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 3 Interventional

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822
View directory record Official record
Conditions
Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions
Alfuzosin (SL770499)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older · Male only
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2008 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization

NCT00465101
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
GreenLight HPS
Device
Lead sponsor
American Medical Systems
Industry
Eligibility
45 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Middlebury, Connecticut • Roswell, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jul 22, 2026, 12:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ejaculatory-Sparing HoLEP vs Standard HoLEP

NCT07631286
View directory record Official record
Conditions
Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Ejaculatory-sparing (ES-sparing) HoLEP
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 3 Interventional

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

NCT01966614
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug · Other
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years and older · Male only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia

NCT01500057
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Greenlight XPS Laser, BiVAP Saline Vaporization of the prostate
Device
Lead sponsor
Brooklyn Urology Research Group
Other
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 1Phase 2 Interventional

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

NCT01454349
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Laguna Hills, California • Long Beach, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Jul 22, 2026, 12:13 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

NCT00044226
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
ML-04A
Drug
Lead sponsor
Milkhaus Laboratory
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
14
States / cities
Mobile, Alabama • Fair Oaks, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 12:13 PM EDT
Terminated No phase listed Observational

Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate

NCT00169767
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Comparison study between KTP and HoLAP for BPH
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Westland, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT00427219
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 22, 2026, 12:13 PM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 22, 2026, 12:13 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)

NCT01912339
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Interventions
Rezum System, Rigid Cystoscopy
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Denver, Colorado • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jul 22, 2026, 12:13 PM EDT
Not listed Phase 1 Interventional

Study of the Effects of Pomegranate Tablets on Enlarged Prostates

NCT00381108
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo Tablet, Pomegranate Tablet
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Jul 22, 2026, 12:13 PM EDT
Terminated Not applicable Interventional Results available

Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia

NCT04398966
View directory record Official record
Conditions
BPH, Enlarged Prostate (BPH), Prostatic Hyperplasia
Interventions
Prostatic Artery Embolization (HydroPearl® compressible microspheres)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 12:13 PM EDT
Withdrawn Not applicable Interventional

Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

NCT03043222
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Urinary Frequency/Urgency, Urinary Incontinence, Urge, Incontinence, Urinary, Nocturia
Interventions
UroLift as artifical device for prostatic urethral lift., Embospheres Microspheres as embolic agents for prostate artery embolization
Device
Lead sponsor
St. Louis University
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 22, 2026, 12:13 PM EDT
Terminated Phase 2 Interventional Results available

Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams

NCT02396420
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Embosphere Microspheres
Device
Lead sponsor
South Florida Medical Imaging, PA
Other
Eligibility
40 Years to 89 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Jul 22, 2026, 12:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
LY500307, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jul 22, 2026, 12:13 PM EDT